Ambria Dermatology Ab

Denovastella Ab

Trophea Development Ab

Hydro Pharma Ab

Jan Faergemann

Thomas Hedner

Olov Sterner

Gudmundur Johannsson

Jörgen Johnsson

Claes Ohlsson

Lars Bjork

Gunnar Swanbeck

Derek Gregory Batcheller

Jan Törnell

Lars Björk

The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit. This study has for the first time shown that a combination of TRIAC and DHEA could effectively stimulate collagen synthesis in skin pretreated with betamethasone valerate demonstrated by an increase in PINP, and that the combination was more effective than TRIAC or DHEA alone. This combination could be used to effectively treat skin atrophy in corticosteroid induced skin atrophy. It could also be used to treat skin atrophy due to other circumstances such as e. g. sun damaged skin and skin atrophy due to high age. Another interesting application would be to combine TRIAC and DHEA with a potent corticosteroid in order to prevent corticosteroid induced skin atrophy. If this combination still is effective in the treatment of eczema and psoriasis and without the risk of skin atrophy this combination will be a major breakthrough for the use of potent topical corticosteroids.

Treatment of skin atrophy with a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA)

The invention relates to the use of at least davanone and 1,8-cineol for the manufacture of an antimicrobial and/or antiinflammatory composition as well as a method of producing said composition.

Antimicrobial and antiinflammatory composition

The present invention relates to a composition comprising at least 3 different diols, wherein said diols have the general structure (CH)HO, wherein n is the number of CHand being between 3 to 10, in a total amount of from about 0.1 to about 50% (v/v), a method for producing the composition and its use, such as in therapy. The composition may be a pharmaceutical, cosmetic, antimicrobial or preservative composition. The composition is useful in inactivating microorganisms or preventing their growth.

Composition comprising at least 3 different diols

A topical composition for skin care or administration of a pharmacologically active agent in form of a lotion, cream or similar comprises from 5% to 70% by weight of pentane-1,5-diol and a cosmetically or pharmaceutically acceptable carrier, with the proviso that the composition does not comprise polysiloxane, volatile siloxane, phosphatidyl-choline, creatine, carnitine, panthenol, pyruvic acid, monoglyceride of lauric acid, monoglyceride of myristic acid. Also disclosed are corresponding methods of administration, a patch for holding said composition against the skin, and methods of preventing or treating a dry skin condition and of keeping skin in a humid state.

Potentiated topical composition

A method for inhibiting the growth of multiple-resistant bacteria comprises the topical administration of a pharmaceutical composition comprising 15% by weight or more of pentane-1,5-diol and a pharmaceutical acceptable carrier. Also disclosed is a method of preparing a corresponding medicament. A method of disinfecting a surface contaminated with multiple-resistant bacteria comprises providing a disinfecting composition comprising 15% or more by weight of pentane-1,5-diol and an aqueous carrier, applying the composition to the surface; optionally, keeping it in contact with the surface for a period of time from 5 min to 24 hrs at ambient temperature, and rinsing the surface with water or an aqueous detergent composition. Also disclosed is the use of a corresponding bacteriostatic composition.

Method for inhibiting the growth of antibiotic resistant of bacteria by using pentane-1,5-diol

A preparation for topical treatment of infections caused by virus, bacteria and fungi, said preparation contains pentane diol or hexane diol as active substance.

Growing community of inventors

Göteborg, Sweden

Jan Faergemann